| Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule MB Nasr, V Usuelli, S Dellepiane, AJ Seelam, TV Fiorentino, F D’Addio, ... Cell Metabolism 36 (6), 1302-1319. e12, 2024 | 18 | 2024 |
| Effect of prolonged and substantial weight loss on incident atrial fibrillation: a systematic review and meta-analysis AE Pontiroli, L Centofanti, CW Le Roux, S Magnani, E Tagliabue, F Folli Nutrients 15 (4), 940, 2023 | 8 | 2023 |
| Mechanisms of action of incretin receptor based dual-and tri-agonists in pancreatic islets F Folli, G Finzi, R Manfrini, A Galli, F Casiraghi, L Centofanti, C Berra, ... American Journal of Physiology-Endocrinology and Metabolism 325 (5), E595-E609, 2023 | 7 | 2023 |
| Alanine transferase levels (ALT) and triglyceride-glucose index are risk factors for type 2 diabetes mellitus in obese patients F Folli, AE Pontiroli, AS Zakaria, L Centofanti, E Tagliabue, L La Sala Acta Diabetologica 61 (4), 435-440, 2024 | 3 | 2024 |
| Obesity effect on newly diagnosed and recurrent post-ablation atrial fibrillation: A systematic review and meta-analysis F Folli, L Centofanti, S Magnani, E Tagliabue, M Bignotto, L La Sala, ... Journal of endocrinological investigation 47 (5), 1051-1066, 2024 | 2 | 2024 |
| Effects of Melatonin on Exercise-Induced Oxidative Stress in Adults with Obesity Undergoing a Multidisciplinary Body Weight Reduction Program AE Rigamonti, FM Rubino, D Caroli, A Bondesan, S Mai, SG Cella, ... Journal of Clinical Medicine 13 (17), 5216, 2024 | 1 | 2024 |
| Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting … C Berra, R Manfrini, F Bifari, E Cipponeri, R Ghelardi, L Centofanti, ... Pharmacological Research 210, 107517, 2024 | | 2024 |
| The triglyceride-glucose index, blood glucose levels, and metabolic syndrome are associated with all-cause mortality in obesity AE Pontiroli, L Centofanti, AS Zakaria, S Cerutti, M Dei Cas, R Paroni, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews 18 (10), 103146, 2024 | | 2024 |
| Synergistic effects of glucose tolerance and BMI on cardiovascular events and all-cause mortality in a healthy population: CA. ME. LI. A study 7 years follow-up M Bignotto, E Bianco, L Centofanti, A Russo, M Dei Cas, P Zermiani, ... American Journal of Physiology-Endocrinology and Metabolism 327 (4), E498-E511, 2024 | | 2024 |
| Investigating the Impact of Epstein-Barr Virus on Sphingolipid Composition in Extracellular Vesicles of Multiple Sclerosis Patients L Centofanti, A Zollo, M Dei Cas, V Citro, D Giannandrea, ... | | 2024 |
| fPCe=> ress Cell Metabolism MB Nasr, V Usuelli, S Dellepiane, AJ Seelam, TV Fiorentino, F D’Addio, ... Cell Metabolism 36, 1302-1319, 2024 | | 2024 |
| THU-285 Lownonpsychedelic dosed of psilocybin for the therapy of MASLD M Colognesi, D Gabbia, A Rinaldi, L Cascione, I Zanotto, S Comai, ... Journal of Hepatology 80, S592-S593, 2024 | | 2024 |
| Non-psychedelic doses of psilocybin as a novel therapeutic approach for MASLD S De Martin, D Gabbia, M Colognesi, A Rinaldi, L Cascione, I Zanotto, ... Digestive and Liver Disease 56, S60, 2024 | | 2024 |
| The Relationship of Glucose Intolerance/Diabetes and Overweight/Obesity with Sphingolipidoma Alterations C Morano, L Centofanti, MV DEI CAS, S Penati, E Bianco, M Bignotto, ... | | 2024 |
| THE SEROTONIN RECEPTOR AGONIST PSILOCYBIN AS A NOVEL THERAPEUTIC APPROACH FOR NAFLD: PRECLINICAL STUDIES S De Martin, D Gabbia, M Colognesi, I Zanotto, K Sayaf, S Comai, ... HEPATOLOGY 78, S1222-S1223, 2023 | | 2023 |
| Comment on: Risk of non-hormonal cancer after bariatric surgery: meta-analysis of retrospective observational studies AE Pontiroli, V Ceriani, M Tagliabue, L Centofanti, E Tagliabue British Journal of Surgery 110 (5), 618-618, 2023 | | 2023 |
| GLP1R Strives T Cell Negative Costimulation Through a rRNA Gene Repressor Interactome M Ben Nasr, V Usuelli, S Dellepiane, AJ Seelam, TV Fiorentino, F D’Addio, ... | | |
